Rhumbline Advisers cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.5% during the 4th quarter, according to the company in its most recent ...
As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced ...
Q4 2024 Earnings Call Transcript February 19, 2025 Charles River Laboratories International, Inc. beats earnings expectations ...
Barclays lowered the firm’s price target on Charles River (CRL) to $160 from $166 and keeps an Equal Weight rating on the shares post the Q4 ...
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.
4d
Zacks.com on MSNCRL Stock Up on Q4 Earnings and Revenue Beat, Margins FallCharles River Laboratories International, Inc. CRL reported fourth-quarter 2024 adjusted earnings per share (EPS) of $2.66, ...
Charles River Laboratories International Inc. (CRL) on Wednesday reported a loss of $215.7 million in its fourth quarter. The ...
New York State Teachers Retirement System decreased its holdings in shares of Charles River Laboratories International, Inc. ...
Analysts have set 12-month price targets for Charles River, revealing an average target of $185.0, a high estimate of $210.00 ...
Analysts fell to the sidelines weighing in on DaVita (DVA – Research Report) and Charles River Labs (CRL – Research Report) with neutral ...
Predatory lending is rampant in low-income communities, draining over $2.4 billion from cash-strapped borrowers. Protect your finances and support responsible lending policies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results